Compare Novo Nordisk A/S (NVO) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tenet Healthcare Corporation — how do they compare? Novo Nordisk A/S trades at $45.88 (market cap $207.85B), while Tenet Healthcare Corporation trades at $259.45 (market cap $20.89B). The key difference: Novo Nordisk A/S is far larger — about 9.9× Tenet Healthcare Corporation's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| NVO | THC | |
|---|---|---|
Market Cap | $207.85B | $20.89B |
Sector | Health | Health |
52-Week High | $63.98 | $262.63 |
52-Week Low | $35.29 | $161.37 |
Enterprise Value | $222.55B | $31.97B |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tenet Healthcare (THC) trades at $262.13, up 2.14% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS beating estimates at $6.12 versus $4.26 expected, while valuation metrics remain attractive with P/E of 10.05 and EV/EBITDA of 5.74. Recent institutional buying and positive earnings revisions support the upward trend.
Outlook remains positive with consensus price target of $281.44 offering 7.4% upside potential. Key risks include healthcare policy headwinds and competitive pressures, but strong ambulatory growth and expense management provide fundamental support. The stock presents a compelling value-growth combination for investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
